A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
As airports grow more complex, the real innovation lies in making their systems simpler, faster, and easier to act on
Updated
March 24, 2026 5:55 PM
An airplane parked at Josep Tarradellas Barcelona-El Prat Airport. PHOTO: UNSPLASH
Airports are some of the most complex systems in the world. Every day, they manage thousands of flights, passengers, crew schedules, gates and ground operations—all moving at the same time. But much of this still runs on older software that doesn’t connect well, making simple decisions harder than they need to be.
This is the gap companies like AirportLabs are trying to address. Instead of relying on multiple disconnected systems, their approach brings airport operations into one cloud-based platform. The goal is straightforward: take scattered data and turn it into something teams can actually use in real time.
In practice, this means combining core systems like flight databases, resource management and display systems into a single interface. When everything is connected, airport staff can respond faster—whether it’s adjusting gate assignments, managing delays, or coordinating ground crews. Rather than reacting late, decisions can be made as situations unfold.
Another shift is how this technology is built. Traditional airport systems often require heavy on-site infrastructure and long deployment timelines. In contrast, cloud-based platforms remove much of that complexity. Updates are faster, systems are easier to scale and teams spend less time maintaining servers and more time improving operations.
What stands out is the speed of adoption. Instead of multi-year rollouts, newer systems can be implemented in weeks, allowing airports to see improvements much sooner.
At a broader level, this reflects a familiar pattern seen across industries. As operations become more data-heavy, the advantage shifts to those who can simplify complexity. In aviation, that doesn’t just mean better technology—it means making the entire system easier to run.